TABLE 3.
Correlation of pathological measures with rs5848 in the ROSMAP cohort
| Unadjusted model | Adjusted for age and sex | Adjusted for age, sex, and AD status | Adjusted for age, sex, and APOE ε4 dosage | |||||
|---|---|---|---|---|---|---|---|---|
| Correlation coefficient | P‐value | Correlation coefficient | P‐value | Correlation coefficient | P‐value | Correlation coefficient | P‐value | |
| Global pathology a | −0.02 | 4.45E‐01 | −0.02 | 4.84E‐01 | −0.03 | 3.76E‐01 | −0.03 | 3.47E‐01 |
| Braak Stage | −0.03 | 3.40E‐01 | −0.02 | 4.91E‐01 | −0.02 | 4.14E‐01 | −0.02 | 4.86E‐01 |
| Diffuse plaque burden | −0.01 | 6.26E‐01 | −0.01 | 6.73E‐01 | −0.01 | 6.56E‐01 | −0.02 | 5.54E‐01 |
| Neuritic plaque burden | −0.01 | 6.86E‐01 | −0.01 | 7.06E‐01 | −0.01 | 6.57E‐01 | −0.02 | 5.57E‐01 |
| Square‐root of tangle density across eight brain regions | −0.02 | 5.22E‐01 | −0.01 | 6.64E‐01 | −0.02 | 5.87E‐01 | −0.02 | 5.34E‐01 |
| Square‐root of the overall amyloid levels | −0.02 | 5.78E‐01 | −0.01 | 7.51E‐01 | −0.01 | 6.76E‐01 | −0.02 | 5.51E‐01 |
| Hippocampal sclerosis (present/absent), | 0.08 | 4.88E‐03 | 0.09 | 3.08E‐03 | 0.09 | 3.09E‐03 | 0.08 | 4.55E‐03 |
| TPD‐43 pathology (present/absent) | 0.08 | 1.84E‐02 | 0.08 | 1.00E‐02 | 0.08 | 9.52E‐03 | 0.08 | 1.65E‐02 |
| Presence of Lewy bodies | 0.00 | 8.82E‐01 | 0.00 | 9.00E‐01 | 0.00 | 9.08E‐01 | 0.00 | 9.62E‐01 |
| Synaptic measure b | 0.00 | 9.68E‐01 | 0.00 | 9.76E‐01 | 0.00 | 9.37E‐01 | 0.00 | 9.88E‐01 |
Abbreviation: ROSMAP, Religious Orders Study and Memory and Aging Project.
a
Global pathology defined as global measure of pathology based on the scaled scores of pathology in five brain regions, where the scaled variable is the original count divided by the standard deviation.
b
Synaptic measure across three cortical (hippocampus, midfrontal cortex, and inferior temporal).